Cargando…
Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629808/ https://www.ncbi.nlm.nih.gov/pubmed/36322403 http://dx.doi.org/10.18632/oncotarget.28127 |
_version_ | 1784823471163834368 |
---|---|
author | Gimotty, Phyllis A. Till, Jacob E. Udgata, Shirsa Takenaka, Naomi Yee, Stephanie S. LaRiviere, Michael J. O’Hara, Mark H. Reiss, Kim A. O’Dwyer, Peter Katona, Bryson W. Herman, Daniel Carpenter, Erica L. Zaret, Kenneth S. |
author_facet | Gimotty, Phyllis A. Till, Jacob E. Udgata, Shirsa Takenaka, Naomi Yee, Stephanie S. LaRiviere, Michael J. O’Hara, Mark H. Reiss, Kim A. O’Dwyer, Peter Katona, Bryson W. Herman, Daniel Carpenter, Erica L. Zaret, Kenneth S. |
author_sort | Gimotty, Phyllis A. |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9629808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-96298082022-11-04 Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma Gimotty, Phyllis A. Till, Jacob E. Udgata, Shirsa Takenaka, Naomi Yee, Stephanie S. LaRiviere, Michael J. O’Hara, Mark H. Reiss, Kim A. O’Dwyer, Peter Katona, Bryson W. Herman, Daniel Carpenter, Erica L. Zaret, Kenneth S. Oncotarget Correction Impact Journals LLC 2022-11-02 /pmc/articles/PMC9629808/ /pubmed/36322403 http://dx.doi.org/10.18632/oncotarget.28127 Text en Copyright: © 2022 Gimotty et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Correction Gimotty, Phyllis A. Till, Jacob E. Udgata, Shirsa Takenaka, Naomi Yee, Stephanie S. LaRiviere, Michael J. O’Hara, Mark H. Reiss, Kim A. O’Dwyer, Peter Katona, Bryson W. Herman, Daniel Carpenter, Erica L. Zaret, Kenneth S. Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma |
title | Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma |
title_full | Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma |
title_fullStr | Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma |
title_full_unstemmed | Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma |
title_short | Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma |
title_sort | correction: thbs2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma |
topic | Correction |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629808/ https://www.ncbi.nlm.nih.gov/pubmed/36322403 http://dx.doi.org/10.18632/oncotarget.28127 |
work_keys_str_mv | AT gimottyphyllisa correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT tilljacobe correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT udgatashirsa correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT takenakanaomi correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT yeestephanies correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT larivieremichaelj correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT oharamarkh correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT reisskima correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT odwyerpeter correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT katonabrysonw correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT hermandaniel correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT carpentererical correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma AT zaretkenneths correctionthbs2asaprognosticbiomarkerforpatientsdiagnosedwithmetastaticpancreaticductaladenocarcinoma |